A comprehensive view of Daiichi Sankyo Company Ltd.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Lung Cancer Research Foundation partners with Daiichi Sankyo, AstraZeneca to fund up to three research grants focused on antibody drug conjugates to treat lung cancer; grants to support research into HER2 directed and TROP2 directed ADCs
Published: March 16, 2023 by Associated Press
China NMPA approves AstraZeneca & Daiichi Sankyo's Enhertu to treat HER2-positive metastatic breast cancer treated with one or more prior anti-HER2-based regimens
Published: February 27, 2023 by PharmaBiz (India)
AstraZeneca and Daiichi Sankyo partner with Ibex Medical Analytics to collaborate on developing, clinically validating Ibex’s AI-powered Galen Breast HER2 IHC scoring product for breast cancer patients; breast cancer most common cancer in women
Published: February 07, 2023 by Clinical Lab Products
AstraZeneca and Daiichi Sankyo’s Enhertu approved in the EU as the first HER2-directed therapy for patients with HER2-low metastatic breast cancer; in Europe, about 531,000 breast cancer patients are diagnosed annually with around 141,000 deaths
Published: January 26, 2023 by AstraZeneca AB
Astellas Pharma, Eisai, Daiichi Sankyo and Takeda to collaborate in development of more environmentally friendly packaging for pharmaceutical products; potential solutions could include blister packs made of biomass-based plastic
Published: December 22, 2022 by PR Newswire

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count